Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Lactoferricin but not lac… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Lactoferricin but not lactoferrin inhibit herpes simplex virus type 2 infection in mice.

Artikel i vetenskaplig tidskrift
Författare Andrey Shestakov
Håvard Jenssen
Inger Nordström
Kristina Eriksson
Publicerad i Antiviral research
Volym 93
Nummer/häfte 3
Sidor 340-5
ISSN 1872-9096
Publiceringsår 2012
Publicerad vid Institutionen för medicin, avdelningen för reumatologi och inflammationsforskning
Sidor 340-5
Språk en
Länkar dx.doi.org/10.1016/j.antiviral.2012...
Ämnesord Animals, Antiviral Agents, administration & dosage, Cattle, Cell Line, Female, Herpes Genitalis, drug therapy, virology, Herpesvirus 2, Human, drug effects, physiology, Humans, Lactoferrin, administration & dosage, Mice, Mice, Inbred C57BL
Ämneskategorier Immunbiologi, Medicinsk mikrobiologi

Sammanfattning

We have evaluated the potential of bovine lactoferrin and lactoferricin for their ability to prevent and/or treat genital HSV-2 infection in mice. We confirm previous data showing that both lactoferrin and lactoferricin have antiviral properties in vitro and can inhibit HSV-2 infection of GMK cells in a dose-dependent manner. When tested in vivo, lactoferricin but not lactoferrin was also a potent inhibitor of HSV-2 infection. When admixed with virus prior to inoculation, lactoferricin inhibited disease development and significantly reduced the viral load in a genital model of HSV-2 infection in mice. Lactoferrin and lactoferricin were also tested for their ability to stimulate the production of chemokines. Neither of the compounds induced the production of CCL3, CCL5, CXCL1 or CXCL2 by mouse splenocytes in vitro. However, when tested in vivo, both lactoferrin and lactoferricin were able to induce local vaginal production of CCL5. Lactoferrin also induced CXCL2 production. The prophylactic and/or therapeutic effects of lactoferrin or lactoferricin were also tested. But none of the compounds were efficient in blocking HSV-2 infection when given 24h prior to HSV-2 infection. Lactoferricin however showed promising results as a therapeutic agent and delayed both disease onset by 3days as well as reducing the viral load almost 15-fold when given as a single dose 24h post-infection. These data show that lactoferricin can block genital herpes infection in mice, and perhaps also be used for post-infection treatment.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?